Plain-English translation of NCT07330674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new oral medication called for people with age-related macular degeneration (AMD), a condition that causes vision loss. The study is being conducted in three phases: first, healthy volunteers will take a single dose to check safety; second, healthy volunteers will take multiple doses over time; and third, people who actually have AMD will take the medication daily. Researchers will monitor safety, side effects, and how the body processes the medication.
Age-related macular degeneration is a serious eye condition that gradually destroys central vision in older adults. This medication is being tested because it may help slow or prevent this vision loss, offering a new treatment option for people living with AMD.
You likely qualify if…
You likely don't qualify if…
If you join, you will take capsules by mouth—either a single dose or daily doses over several weeks, depending on which part of the study you're in. You'll have blood samples taken to help researchers understand how your body processes the medication, and your eyes will be examined regularly to check for any changes. The study is double-blind in the early phases, meaning neither you nor the researchers will know whether you're receiving the actual medication or a placebo, which helps ensure unbiased results.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Aptabio Therapeutics, Inc.
Enrollment target
~68 participants
Started
February 2026
Primary completion
November 2027
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Center, Clinical Center
Aptabio Therapeutics, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.